Financhill
Back

Tourmaline Bio Quote, Financials, Valuation and Earnings

Tourmaline Bio Price Quote

$25.88
-0.16 (-0.61%)
(Updated: December 2, 2024 at 12:20 PM ET)

Tourmaline Bio Key Stats

Sell
48
Tourmaline Bio (TRML) is a Sell

Day range:
$25.41 - $26.65
52-week range:
$12.12 - $48.31
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
2.08%

Volume:
112.1K
Avg. volume:
189.4K
1-year change:
41.37%
Market cap:
$667.7M
Revenue:
$0
EPS:
$-2.64

How Much Does Tourmaline Bio Make?

Data Unavailable

Is Tourmaline Bio Growing As A Company?

Data Unavailable

Tourmaline Bio Stock Price Performance

  • Did Tourmaline Bio Stock Go Up Last Month?
    Tourmaline Bio share price went down by -3.91% last month
  • Did TRML's Share Price Rise Over The Last Year?
    TRML share price rose by 41.37% over the past 1 year

What Is Tourmaline Bio 52-Week High & Low?

Tourmaline Bio Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Tourmaline Bio?

  • How Much Debt Does Tourmaline Bio Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Tourmaline Bio Have?
    Cash and short term investments quarterly total is $281.9M
  • What Is Tourmaline Bio’s Book Value Per Share?
    Book value per share is 12.52

Is Tourmaline Bio Cash Flow Positive?

  • What Is TRML Cash Flow From Operations?
    Cash flow from operations (TTM) is -$65.7M
  • What Is Tourmaline Bio’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $229.5M
  • What Is Tourmaline Bio’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$206.8M

Tourmaline Bio Return On Invested Capital

Data Unavailable

Tourmaline Bio Earnings Date & Stock Price

Tourmaline Bio Competitors

  • Who Are Tourmaline Bio's Competitors?
    Below is a list of companies who compete with Tourmaline Bio or are related in some way:
    • AIM ImmunoTech Inc (AIM)
    • CEL-SCI Corp (CVM)
    • IGC Pharma Inc (IGC)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Protalix BioTherapeutics Inc (PLX)

Tourmaline Bio Dividend Yield

Tourmaline Bio Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 8.45%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 5
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 58.50
Upside from Last Price: 124.65%

Major Shareholders

  • How many TRML shares are owned by institutional investors?
    31.7M TRML shares are owned by institutional investors
  • How many TRML shares are owned by insiders?
    1.6M TRML shares are owned by insiders